文献速递甲状腺疾病

老年人亚临床甲状腺功能减退症

Subclinical hypothyroidism in older individuals.
PubMed 文献 · Lancet Diabetes Endocrinol · 2021-12-22

本文综述近十年发表的荟萃分析、随机临床试验和队列研究,评估65岁及以上人群亚临床甲状腺功能减退症的临床意义与治疗。数据显示促甲状腺激素4·5-7·0 mIU/L者心血管、骨骼肌肉及认知不良结局发生率与甲状腺功能正常组无显著差异,左甲状腺素治疗未改善症状及心脏骨骼参数;建议促甲状腺激素持续≥7 mIU/L者考虑治疗,<7 mIU/L者不启动治疗,剂量按年龄、合并症和预期寿命个体化。

要点

  • 65岁及以上人群促甲状腺激素4·5-7·0 mIU/L时不良结局与甲状腺功能正常组无显著差异
  • 老年亚临床甲状腺功能减退症患者左甲状腺素治疗未改善症状及心脏骨骼参数
  • 促甲状腺激素持续≥7 mIU/L者可考虑左甲状腺素治疗,<7 mIU/L者不启动治疗

核心结论

  • 65岁及以上亚临床甲状腺功能减退症患者促甲状腺激素持续≥7 mIU/L时可考虑左甲状腺素治疗,<7 mIU/L时不启动治疗。
  • 左甲状腺素剂量应根据年龄、合并症和预期寿命个体化。

研究设计与样本

  • 叙述性综述,评估近十年发表的关于65岁及以上人群亚临床甲状腺功能减退症临床意义与治疗的数据。
  • 讨论的文献类型包括荟萃分析、随机临床试验和队列研究。

主要发现

  • 65岁及以上人群促甲状腺激素4·5-7·0 mIU/L与甲状腺功能正常组相比,心血管、骨骼肌肉或认知不良结局发生率无显著增加。
  • 老年亚临床甲状腺功能减退症患者经左甲状腺素治疗后,甲状腺功能减退症状及心脏和骨骼参数未改善。

关键数值与推荐

  • 亚临床甲状腺功能减退症定义为促甲状腺激素高于参考范围(一般4·5 mIU/L或更高)且游离甲状腺素浓度正常。
  • 国际指南对老年亚临床甲状腺功能减退症的管理推荐存在差异。

临床怎么用

  • 作者认为,65岁及以上亚临床甲状腺功能减退症患者促甲状腺激素持续≥7 mIU/L时可考虑左甲状腺素治疗。
  • 作者认为,促甲状腺激素<7 mIU/L时不启动左甲状腺素治疗。
  • 左甲状腺素剂量应根据年龄、合并症和预期寿命个体化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Subclinical hypothyroidism, which is defined as a thyroid-stimulating hormone concentration higher than the reference range (generally 4·5 mIU/L or higher) with normal free thyroxine concentrations, is frequently found in older individuals. International guidelines differ in recommendations for management of subclinical hypothyroidism in older individuals. We assessed published data during the past decade on the clinical significance and treatment of subclinical hypothyroidism in individuals aged 65 years and older. Meta-analyses, randomised clinical trials, and cohort studies are discussed in this narrative Review. Studies showed no significantly increased incidence in adverse cardiovascular, musculoskeletal, or cognitive outcomes in individuals aged 65 years or older when serum thyroid-stimulating hormone concentration was 4·5-7·0 mIU/L versus a euthyroid group. Moreover, in older individuals with subclinical hypothyroidism, symptoms of hypothyroidism and cardiac and bone parameters did not improve after levothyroxine treatment. These data suggest that treatment with levothyroxine should be considered for individuals aged 65 years or older with subclinical hypothyroidism when thyroid-stimulating hormone concentration is persistently 7 mIU/L or higher and to not initiate treatment with thyroid-stimulating hormone concentrations of less than 7 mIU/L. Levothyroxine doses should be personalised according to age, comorbidities, and life expectancy.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Biondi B, Cappola AR. Subclinical hypothyroidism in older individuals. Lancet Diabetes Endocrinol. 2021. PMID: 34953533. doi:10.1016/S2213-8587(21)00285-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。